DelveInsight reports that more than four key companies are actively engaged in developing over four treatment therapies for Tendonitis.
Tendonitis Overview:
Tendonitis, also called tendinopathy, is the inflammation of a tendon — the tough connective tissue that links muscles to bones. It often develops due to injury, trauma, or repetitive joint movements. Based on the affected area, it may be referred to by specific names such as Achilles tendonitis or tennis elbow.
The condition commonly impacts the elbows, heels, shoulders, and wrists. Standard treatment includes rest, pain-relief medications, and anti-inflammatory drugs, while physical therapy helps strengthen muscles and support recovery. In more severe cases, surgical intervention may be necessary to repair the damaged tendon.
Request for a detailed insights report on Tendonitis pipeline insights @ https://www.delveinsight.com/report-store/tendonitis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
"Tendonitis Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Tendonitis Therapeutics Market.
Key Takeaways from the Tendonitis Pipeline Report
-
DelveInsight’s Tendonitis pipeline report highlights a strong development landscape, with over four active companies working on more than four therapies for treating Tendonitis.
-
Key players in this space include Seikagaku Corporation, MetrioPharm, MiMedx, Zhejiang Xingyue Biotechnology Co., Ltd., R3 Stem Cell, Dobecure, Causeway Therapeutics, and others, all aiming to introduce innovative drugs to enhance treatment options.
-
Notable pipeline candidates currently in various stages of development include SI-613, MP1032, and others.
-
In addition, device-based innovations are emerging — for instance, TendoNova’s Ocelot, a handheld tool for mechanically fragmenting and debriding targeted tendon tissues, received FDA 510(k) clearance in May 2022 for commercial use in conditions such as tennis elbow and plantar fasciitis. Similarly, in May 2022, CoNextions Inc. secured FDA 510(k) clearance for a device designed to improve healing and functional outcomes in tendon repair surgeries.
Tendonitis Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights into the key companies that are developing therapies in the Tendonitis Market.
-
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Tendonitis treatment.
-
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Tendonitis market.
Download our free sample page report on Tendonitis pipeline insights
Tendonitis Emerging Drugs
-
SI-613: Seikagaku Corporation
-
MP1032: MetrioPharm
Tendonitis Companies
Around four major companies are actively developing therapies for tendonitis, with Seikagaku Corporation having one of the most advanced drug candidates currently in Phase II clinical trials.
DelveInsight’s report covers around 4+ products under different phases of clinical development like
-
Late stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I) along with the details of
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
Tendonitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Intravenous
-
Subcutaneous
-
Oral
-
Intramuscular
Tendonitis Products have been categorized under various Molecule types such as
-
Monoclonal antibody
-
Small molecule
-
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Tendonitis Therapies and Key Companies: Tendonitis Clinical Trials and advancements
Tendonitis Pipeline Therapeutic Assessment
• Tendonitis Assessment by Product Type
• Tendonitis By Stage
• Tendonitis Assessment by Route of Administration
• Tendonitis Assessment by Molecule Type
Download Tendonitis Sample report to know in detail about the Tendonitis treatment market @ Tendonitis Therapeutic Assessment
Table of Content
1. Report Introduction
2. Executive Summary
3. Tendonitis Current Treatment Patterns
4. Tendonitis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Tendonitis Late-Stage Products (Phase-III)
7. Tendonitis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Tendonitis Discontinued Products
13. Tendonitis Product Profiles
14. Tendonitis Key Companies
15. Tendonitis Key Products
16. Dormant and Discontinued Products
17. Tendonitis Unmet Needs
18. Tendonitis Future Perspectives
19. Tendonitis Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Tendonitis Pipeline Reports Offerings
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
